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Abstract
Background: We aimed to evaluate the efficiency and safety of cis/carboplatin plus gemcitabine, which was
previously used for mesothelioma but with no recorded proof of its efficiency, compared with cis/carboplatin
plus pemetrexed, which is known to be effective in mesothelioma, in comparable historical groups of malignant
pleural mesothelioma.
Methods: One hundred and sixteen patients received cis/carboplatin plus pemetrexed (group 1), while 30 patients
received cis/carboplatin plus gemcitabine (group 2) between June 1999 and June 2012. The two groups were
compared in terms of median survival and adverse events to chemotherapy.
Results: The mean ages of groups 1 and 2 were 60.7 and 60.8 years, respectively. Most of the patients (78.1 %)
had epithelial type tumors, and 47 % of the patients had stage IV disease. There was no difference between the
two groups in terms of age, gender, asbestos exposure, histology, stage, Karnofsky performance status, presence
of pleurodesis, prophylactic radiotherapy, second–line chemotherapy and median hemoglobin and serum albumin
levels. The median survival time from diagnosis to death or the last day of follow up with a 95 % confidence interval
was 12 ± 0.95 months (95 % CI: 10.15–13.85) for group 1 and 11.0 ± 1.09 months (95 % CI: 8.85–13.15) for group 2
(Log-Rank: 0.142; p = 0.706). The median survival time from treatment to death or the last day of follow-up with a
95 % confidence interval was 11.0 ± 0.99 months (95 % CI: 9.06–12.94) for group 1 and 11.0 ± 1.52 months (95 % CI:
8.02–13.97) for group 2 (Log-Rank: 0.584; p = 0.445).
The stage and Karnofsky performance status were found to be significant variables on median survival time by
univariate analysis. After adjusting for the stage and Karnofsky performance status, the chemotherapy schema
was not impressive on median survival time (OR: 0.837; 95 % CI: 0.548–1.277; p = 0.409). The progression free survival
was 7.0 ± 0.61 months for group I and 6.0 ± 1.56 months for group II (Log-Rank: 0.522; p = 0.470). The treatment was
generally well tolerated, and the side effects were similar in both groups.
Conclusions: The study indicates that platinum-based gemcitabine is effective and a safe schema in malignant pleural
mesothelioma. Further research should include large randomized phase III trials comparing these agents.
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Background
Malignant pleural mesothelioma (MPM) is an aggres-
sive tumor and remains a significant worldwide health
problem because of its poor prognosis and increasing
incidence [1]. Most of the patients have advanced dis-
ease at diagnosis and are not eligible for multimodality
treatment. Platinum–based chemotherapy is the most
effective systemic therapy in patients with advanced
stage disease. Currently, following a randomized phase
III study, the combination of cisplatin and pemetrexed
is widely used for the systemic treatment of advanced
disease [2]. Another randomized phase III study of
cisplatin and raltitrexed in MPM showed similar results
[3]. However, there is currently no universally accepted
standard chemotherapeutic regimen for MPM.
The combination of cisplatin and gemcitabine was
widely used for MPM throughout the world before the
combination of antifolates and platinum compounds.
Some studies reported that the combination of platinum
and gemcitabine is also a reasonable first–line option for
the systemic therapy of MPM because of its acceptable
toxicity profile, good response and survival rates, and
symptom-relieving effects [4–11]. Although gemcitabine
in combination with cisplatin or carboplatin shows
definite activity in MPM, given the lack of phase III
evidence, the use of gemcitabine as a first–line therapy
is not supported. Gemcitabine in combination with plat-
inum or alone is being used in the clinic as a second–line
regimen for MPM.
There are few studies compared the two regimens. They
showed that platinum – based doublets might represent
similar therapeutic activity in MPM [12–14]. Pemetrexed
is an expensive agent, and when it is used, folic acid and
vitamin B12 supplementation are required to reduce the
toxicity. In our study, we aimed to evaluate the efficiency
and safety of cis/carboplatin plus gemcitabine compared
with cis/carboplatin plus pemetrexed, in comparable his-
torical groups of malignant pleural mesothelioma.
Methods
Patients
Between June 1999 and June 2012, a total of 343 pa-
tients were histologically diagnosed with MPM at the
Chest Disease Department of Eskisehir Osmangazi Uni-
versity Hospital in Turkey. After diagnosis, the best sup-
portive care, chemotherapy, surgery, radiotherapy or
combination therapies were given to the patients in the
Pulmonary Oncology Unit of the Chest Disease Depart-
ment. The study was approved by the Ethical Committee
of Eskisehir Osmangazi University (number: 08.03.2000/
242), and all of the patients provided written informed
consent. A total of 146 patients, who had platinum com-
pounds in combination with gemcitabine or pemetrexed,
were enrolled in this study. The study inclusion criteria
were as follows: no prior therapy except local radiotherapy
to the entry site; measurable or evaluable disease; KPS of
70–100; age greater than 18 years; and adequate bone
marrow (leukocytes ≥ 3000 / μL, granulocytes ≥ 1500 / μL,
hemoglobin ≥ 10 g / dL, and platelets ≥ 100,000 μL), renal
(creatinine ≤ 1.5 mg / dL or creatinine clearance ≥ 60 mL /
min), hepatic (total bilirubin within normal institutional
limits and AST and ALT ≤ 2.5 X upper limit of normal),
and coagulation (prothrombin time international normal-
ized ratio ≤ 1.5) functions were required. All of the
patients provided written informed consent before chemo-
therapy according to our institutional guidelines. One
hundred and ninety-seven patients were excluded from
the study: 81 patients had only the best supportive care;
62 patients had surgical treatment; 22 patients received
different chemotherapeutic regimens as first–line treat-
ment; 2 patients died due to reasons unrelated to MPM or
chemotherapy (pulmonary embolism and pneumonia); 20
patients were not be able to evaluate for a chemotherapy
response; and 10 patients were not followed.
Clinical data, including age, gender, history of asbes-
tos exposure, histology, stage, Karnofsky Performance
Status (KPS), treatment history, side effects, response
to chemotherapy, pleurodesis, prophylactic radiotherapy,
second–line chemotherapy, baseline hemoglobin, base-
line serum albumin and survival characteristics were col-
lected for all the patients. All of the patients were staged
according to the International Mesothelioma Interest
Group (IMIG) staging system [15]. The tumor response
was evaluated using a modified Response Evaluation
Criteria in Solid Tumors (RECIST) [16].
Treatment
The patients were classified into two groups according to
their chemotherapy regimen: 116 patients received cis/
carboplatin and pemetrexed (group 1), and 30 patients
received cis/carboplatin and gemcitabine (group 2). The
two groups were compared in terms of epidemiological,
clinical and survival characteristics. The side effects of
chemotherapy were also recorded.
In the pulmonary oncology unit of our clinic, cis/carbo-
platin and gemcitabine regimen was used as a first – line
chemotherapy regimen until October 2005. Cis/carbopla-
tin and pemetrexed has been used since October 2005.
Gemcitabine 1250 mg/m2 was given intravenously on
days 1 and 8 of a 21-day cycle, followed by intravenous
cisplatin 75 mg/m2 or carboplatin 300 mg/m2 on day 1.
Pemetrexed 500 mg/m2 was given intravenously on day
one, followed by cisplatin 80 mg/m2 or carboplatin
300 mg/m2, intravenously on day 1, which was repeated
every 21 days. Before the administration of pemetrexed,
folic acid, vitamin B12, and dexamethasone supplemen-
tation were provided. Antiemetic therapy with 5-
hydroxytryptamine antagonists and dexamethasone was
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given intravenously on day 1 and, thereafter, orally for 3 to
5 days. Chemotherapy was given for 4 to 6 cycles or until
disease progression, unacceptable adverse events, or pa-
tient unwillingness to chemotherapy. Additionally, the use
of any second-line chemotherapy was recorded. Adverse
events were graded according to the World Health
Organization (WHO) criteria and were assessed before
chemotherapy [17]. All the side effects of chemotherapy
were recorded. Dose adjustments for adverse events were
based on a stepwise reduction schedule.
A history and physical examination, complete blood
count and differential, chemistry panel, electrocardiogram,
chest radiograph, and chest and abdominal computed
tomography (CT) scans were performed at baseline. Bone
scans and brain magnetic resonance imaging were per-
formed only if clinically indicated. Thereafter, the history
and physical examination were performed every 21 days.
The complete blood count and differential and chemistry
panel were performed weekly. The tumor response to
chemotherapy was evaluated by computed tomography
(CT) scans, obtained every two or three cycles of
chemotherapy. Thereafter, CT scans were performed at
3 monthly intervals until disease progression.
Statistical analysis
Data were collected, analyzed, and evaluated in the Lung
and Pleural Cancers Research and Clinical Center of
Eskisehir Osmangazi University. All of the analyses were
performed using a statistical software (SPSS, version 11.5).
The characteristics of the patients, according to their
chemotherapy schedule, were compared using a t-test for
continuous variables and Pearson X2 test or Fisher’s Exact
test for frequency. The median hemoglobin and serum
albumin levels were compared using Mann–Whitney
U test. The median survival times and progression – free
survival with 95 % confidence intervals (CI) were esti-
mated for each group. The survival curves were generated
using the Kaplan – Meier method. All of the patients were
followed until death or for a minimum period of 1 year.
The median survival times were compared between the
chemotherapy groups using both an unadjusted and a
stratified (by stage, histology, KPS) log-rank test. The Cox
proportional hazards regression models were fit to assess
the effect of treatment, stage, histology, KPS, and other
potential prognostic factors of survival. The interactions
between treatments and stratification factors were ex-
plored using the Cox model. The significance level was
considered to be 5 % (p < 0.05), and the approach used
was bilateral.
Results
One hundred and sixteen patients received cis/carboplatin
plus pemetrexed (group 1) between October 2005 and
June 2012, and 30 patients received cis/carboplatin plus
gemcitabine (group 2) between June 1999 and September
2005. The mean ages of groups 1 and 2 were 60.7 and
60.8 years, respectively. The female ratios of groups 1 and
2 were 50 % and 53 %, respectively. Most of the patients
(98 %) were exposed to asbestos for a major part of their
life. Most of the patients (78.1 %) had epithelial type
tumors, and approximately half of them had stage IV
disease (47 %).
There was no difference between the two groups in
terms of age, sex, asbestos exposure, KPS, histological
cell type, stage, presence of pleurodesis, prophylactic
radiotherapy, second–line chemotherapy and baseline
hemoglobin and serum albumin levels (Table 1). These
results showed that they were comparable groups.
There was no significant difference between the ob-
jective response rates to chemotherapy in the two treat-
ment groups: 32.7 % for group I, and 36.7 % for group
II (p = 0.700). The complete response rates were 3.4 %
vs. 6.7 %, while the partial response rates were 29.3 %
vs. 30.0 % in groups I and II, respectively. Stable disease
occurred in 39.7 % and 30 % of the patients in groups I
and II, respectively. The one-year survival rate for
group I was 58.6 % and 56.6 % for group II; the 2–year
survival rate for group I was 20.7 % and 13.3 % for
group II; the 3 – year survival rate was 9.5 % for group
I and 10 % for group II.
The median survival time from diagnosis to death or the
last day of follow-up with a 95 % confidence interval was
12.0 ± 0.95 months (95 % CI: 10.15–13.85) for group 1
and 11.0 ± 1.09 months (95 % CI: 8.85–13.15) for group 2.
The median survival time of the two groups was not
different (Log-Rank: 0.142; p = 0.706). The median survival
time from treatment to death or the last day of follow-up
with a 95 % confidence interval was 11.0 ± 0.99 months
(95 % CI: 9.06–12.94) for group 1 and 11.0 ± 1.52 months
(95 % CI: 8.02–13.97) for group 2 (Log-Rank: 0.584;
p = 0.445) (Fig. 1).
Stage and KPS were found as significant variables of
median survival time by univariate analysis in the two
groups (p = 0.002 and p = 0.045, respectively). After
adjusting for stage and KPS, the chemotherapy regimen
was not impressive on median survival time (OR: 0.837;
95 % CI: 0.548–1.277; p = 0.409).
The progression free survival was 7.0 ± 0.61 months
(95 % CI: 5.079–8.20) for group I and 6.0 ± 1.56 months
(95 % CI: 2.94–9.06) for group II (Log-Rank: 0.522;
p = 0.470) (Fig. 2).
The treatment was generally well tolerated, and the
side effects were similar in both the groups (Table 2).
Discussion
There is currently no widely accepted therapy for MPM.
The necessity for more effective treatments for patients
with mesothelioma is obvious. A number of novel agents
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have been assessed to date. Several classes of drugs are
being explored, including those that affect DNA transcrip-
tion, cell-cycle progression, angiogenesis, and immune
tolerance. Several ongoing or recently completed phase II
and III trials using novel agents such as vorinostat, evero-
limus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine,
bevacizumab, cediranib, and thalidomide have been con-
ducted [18]. Although some of those targeted therapies
have seemed to be promising, none of these agents have
been implemented in daily practice. Therefore, most ef-
forts are directed towards improving standard first-line
therapy with antifolates and platinum compounds, or
developing effective second-line treatments.
Platinum–based chemotherapy seems to be the most
effective systemic therapy in patients with advanced
stage disease. Platinum based gemcitabine was widely
used in the late 1990s and 2000s as a part of phase stud-
ies in MPM because of the synergy between gemcitabine
and platinum compounds [4–11]. In those studies, 9.6 to
13 months of overall survival time and 12 % to 48 % of
the response rates were reported [4–11]. Variable activity
has been observed with gemcitabine and platinum com-
pounds in those studies because of small sample size,
heterogeneity in prognostic factors, and different re-
sponse measurements. Additionally, the symptom con-
trol was better than the control arm in some of these
studies [4, 6, 7, 10]. Although the results have been
variable, the response rate and survival data of the stud-
ies have been encouraging in advanced stage mesotheli-
oma. While some physicians recommend only supportive
care for mesothelioma, platin-based gemcitabine has
become a widely used regimen in front-line chemother-
apy for mesothelioma in some clinics. We used platin-
based gemcitabine before pemetrexed, between June
1999 and September 2005, for mesothelioma in our
clinic in Turkey.










Mean age, years 60.7 ± 10.9 60.8 ± 9.9 0.945
Male: Female 58 : 58 14 : 16 0.745
Asbestos exposure, n (%) 113 (97.4) 29 (96.7) 0.827
Mean Karnofsky
Performance Status
85.7 ± 9.9 80.3 ± 8.7 0.062
Histology, n (%)
Epithelial 92 (79.3) 22 (73.3) 1.00
Sarcomatous 9 (7.8) 2 (6.7)
Mixed 12 (10.3) 5 (16.7)
Unidentified 3 (2.6) 1 (3.3)
Stage, n (%)
I 6 (5.2) 2 (6.7) 0.662
II 12 (10.4) 2 (6.7)
III 41 (35.7) 14 (46.7)
IV 56 (48.7) 12 (40.0)
Pleurodesis, n (%) 41 (35.3) 10 (33.3) 0.837
Prophylactic
radiotherapy, n (%)
22 (19.0) 2 (6.7) 0.083
Second–line
chemotherapy, n (%)
36 (31.0) 8 (26.7) 0.642
Median baseline
hemoglobin, g / dL
12.5 12.3 0.679
Median baseline serum

































































Fig. 1 Median survival by treatment groups
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Two large randomized phase III trials with combina-
tions of antifolate and cisplatin have demonstrated a sur-
vival advantage with this combination compared with
single agent cisplatin [2, 3]. In the trial comparing cis-
platin plus pemetrexed to cisplatin alone, the response
rate with the combination was 41 % in comparison to
17 % with cisplatin [2]. The median survival time was
12.1 months with the combination regimen. In the other
phase III study with raltitrexed, the response rate was
23 %, with a median survival time of 11.4 months [3].
Following the study of Vogelzang et al., platin-based
pemetrexed was approved by the FDA as a first-line
treatment in mesothelioma. Thereafter, within several
years, platinum and antifolate, especially pemetrexed, has
been established as a standard of care in front-line chemo-
therapy for mesothelioma worldwide. Physicians have
some concern about these studies. Neither cisplatin-based
pemetrexed nor raltitrexed were compared with another
doublet. Both studies used only cisplatin in the control
arm. Interestingly, there is not much interest in ralti-
trexed. First, they are expensive agents, especially peme-
trexed. When increasing incidence of mesothelioma is
taken into account, pemetrexed is not cost effective for
most of the patients especially in developing countries.
Additionally, supplementation of folic acid and vitamin
B12 is needed to reduce the toxicity of pemetrexed.
Although, following the study of Vogelzang et al. in
2003, cisplatin-based pemetrexed has been established as
first-line chemotherapy for mesothelioma in most of the
world, gemcitabine and cisplatin is still accepted as an
effective treatment regimen in phase II studies [19, 20].
There is not sufficient number of study compared
platinum based doublets such as pemetrexed, ralti-
trexed, gemcitabine and vinorelbine with one another.
We hypothesize that those doublets that are platin plus
pemetrexed and platin plus gemcitabine may be com-
parable in terms of efficacy and safety, based on previ-
ous phase II studies of gemcitabine. The good response
rate and median survival time observed in our study
suggest that the combination of platin plus gemcitabine
may have similar effects compared to pemetrexed plus
cisplatin.
Lee et al. reviewed platinum analogs with either gem-
citabine or pemetrexed in 81 mesothelioma patients,
retrospectively [12]. They reported similar overall sur-
vival and 1– and 2–year survival rates with both regi-
mens. However, in their study, the survival was better
in the group that was able to receive second–line sys-
temic therapy. Another study comparing gemcitabine
plus cisplatin and pemetrexed plus carboplatin came
from Cairo by Habib et al [13]. They set up a random-
ized phase II study that included 40 patients with
mesothelioma. In their study, the response was superior
in the pemetrexed group (78.9 % vs. 47.6 %). However,
cumulative survival at 1.5 years was similar in the two
groups. Additionally, patients included in the pemetrexed
group were younger than the patients in the gemcitabine
group (49 years old vs. 62 years old; p < 0.001). Age is a
significant prognostic factor in mesothelioma and may be
responsible for the good response to pemetrexed. Another
small study, including total 30 patients, did not show a
significant difference in terms of response rate and overall
survival time between the two groups [14].
In the current study, the regimens were well tolerated
with no toxic deaths. The frequencies and severity of tox-
icities experienced with platin plus gemcitabine or peme-
trexed regimens appear to be comparable to those found
in the literature.
Conclusions
In conclusion, the study indicates that platinum-based
gemcitabine is effective and a safe schema in malignant
pleural mesothelioma. To provide a more cost-effective
treatment approach for advanced MPM, further research
should include randomized controlled phase III trials
comparing platinum doublets plus antifolate and platinum
doublets plus gemcitabine or vinorelbine.
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Table 2 Grade III and IV toxicities according to treatment groups
Toxicity Group I Group II P*
n (%) n (%)
Neutropenia 19 (16.3) 3 (10.0) 0.568
Anemia 4 (3.4) 1 (3.3) 1.000
Thrombocytopenia 6 (5.1) 4 (13.3) 0.123
Nause / vomiting 8 (6.9) 5 (16.6) 0.142
Nephrotoxicity 5 (4.3) - 0.584
Febrile neutropenia 2 (1.7) 2 (6.6) 0.187
Group I: cis/carboplatin + pemetrexed; Group II: cis/carboplatin + gemcitabine;
a: Only the worst WHO grade was reported for each patient
*: Fisher’s Exact Test
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